Stryker Co. (NYSE:SYK) Stock Holdings Decreased by Hancock Whitney Corp

Hancock Whitney Corp lowered its stake in Stryker Co. (NYSE:SYK - Free Report) by 20.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 3,621 shares of the medical technology company's stock after selling 949 shares during the quarter. Hancock Whitney Corp's holdings in Stryker were worth $1,304,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. J. W. Coons Advisors LLC increased its stake in shares of Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company's stock worth $1,315,000 after purchasing an additional 26 shares in the last quarter. Mascoma Wealth Management LLC increased its position in Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after buying an additional 27 shares in the last quarter. Opal Wealth Advisors LLC raised its holdings in shares of Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company's stock worth $654,000 after acquiring an additional 28 shares during the last quarter. Lindbrook Capital LLC lifted its position in shares of Stryker by 2.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after acquiring an additional 28 shares in the last quarter. Finally, Capital & Planning LLC lifted its position in shares of Stryker by 3.6% in the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company's stock valued at $304,000 after acquiring an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Stryker Stock Up 0.4 %

Stryker stock traded up $1.52 during trading on Monday, reaching $366.58. 1,223,251 shares of the company's stock were exchanged, compared to its average volume of 1,356,505. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The firm has a market cap of $139.92 billion, a price-to-earnings ratio of 47.24, a PEG ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The company's 50-day moving average is $367.37 and its two-hundred day moving average is $373.51.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business earned $3.46 earnings per share. On average, analysts predict that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.92%. Stryker's payout ratio is currently 43.30%.

Analysts Set New Price Targets

Several research analysts recently weighed in on SYK shares. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research note on Tuesday, March 4th. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Needham & Company LLC reaffirmed a "buy" rating and issued a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Finally, Stifel Nicolaus lifted their price objective on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.